Pyoderma gangrenosum: Another cutaneous side-effect of sunitinib?

British Journal of Dermatology

Volumn 159, Issue 1, 2008, Pages 242-243

  Ten Freyhaus, K ^a   Homey, B ^b   Bieber, T ^a   Wilsmann Theis, D ^a  

^a UNIVERSITY OF BONN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Pyoderma gangrenosum; Sunitinib; Tyrosine kinase inhibitors

Indexed keywords

PREDNISOLONE; SUNITINIB;

AGED; CASE REPORT; DISEASE COURSE; DOPPLER ECHOGRAPHY; ERYTHEMA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LEG ULCER; LETTER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PYODERMA GANGRENOSUM;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PYODERMA GANGRENOSUM; PYRROLES; TREATMENT OUTCOME;

EID: 45749118676     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08599.x     Document Type: Letter

References (11)

1. Brooklyn T, Dunnill G, Probert C et al. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006 333 : 181 4.
2. Oka M, Berking C, Nesbit M et al. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin grafts. Lab Invest 2000 80 : 595 604.
3. Merkel PA. Drugs associated with vasculitis. Curr Opin Rheumatol 1998 10 : 45 50.
4. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005 6 : 491 500.
5. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003 9 : 327 37.
6. Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003 2 : 471 8.
7. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004 10 : S6388 92.
8. Dib EG, Ifthikharuddin JJ, Scott GA et al. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy. Leuk Res 2005 29 : 233 4.
9. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006 5 : 228 31.
10. Schwarz M, Kreuzer KA, Baskaynak G et al. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002 69 : 254 6.
11. Ayirookuzhi SJ, Ma L, Ramshesh P et al. Imatinib-induced Sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol 2005 141 : 368 70.